SHERIDAN, WYOMING – July 8, 2025 – Bio-Rad Laboratories, Inc. has significantly expanded its presence in the digital PCR market with the launch of four new Droplet Digital™ PCR (ddPCR™) platforms, reinforcing its position as a global leader in life science research and clinical diagnostics. This strategic rollout includes the debut of the QX Continuum™ system and the QX700™ series, the latter resulting from Bio-Rad’s recent acquisition of digital PCR innovator Stilla Technologies.
Comprehensive ddPCR Portfolio Supports Precision and Scalability
By integrating the newly acquired technologies with its established QX200™ and QX600™ systems, Bio-Rad now offers the most comprehensive line of ddPCR instruments on the market. The portfolio includes over 400,000 assays designed to support a wide array of applications in life science and diagnostics.
The enhanced ddPCR offering delivers:
- Industry-leading absolute quantification
- Advanced multiplexing with up to seven-color detection
- Streamlined, simplified workflows
- High-throughput capabilities for sample-intensive labs
“With this launch, our expanded portfolio of instruments, reagents, software, and services extends Bio-Rad’s presence in the genomics research and applied science markets and strengthens our leadership in droplet digital PCR solutions,” said Jim Barry, EVP and President of Bio-Rad’s Life Science Group. “The newly introduced platforms complement Bio-Rad's existing QX ddPCR portfolio and offer our customers unparalleled workflow simplicity and throughput capabilities across the full spectrum of digital PCR applications including oncology, infectious disease, and genetic research.”
QX Continuum Designed for Translational Research
The QX Continuum™ ddPCR system is specifically tailored for translational research applications. It offers a qPCR-like workflow that enhances usability while maintaining flexibility and performance. Its all-in-one design supports four-color multiplexing and up to eight discrete thermal profiles per plate, providing greater control and adaptability for demanding research environments.
QX700 Series Targets Broader Application Demands
The QX700™ series comprises three new digital PCR instruments developed for workflows in academic research, environmental testing, cell and gene therapy, and biopharmaceutical quality control. These systems are built for high-throughput efficiency and streamlined operations.
Key highlights include:
- Seven-color multiplexing
- Capability to process over 700 samples per day
- Minimal input volume requirements
- Continuous loading and easy-to-use software for simplified data analysis
Strategic Growth via Acquisition
The launch of the QX700 series follows Bio-Rad’s acquisition of Stilla Technologies, a move that strengthens the company’s technological base and enhances its ability to meet growing global demand for digital PCR innovations. The integration aligns with Bio-Rad’s strategic priorities of innovation, scalability, and market expansion.
Positioned for the Future of Genomics
Bio-Rad’s expanded ddPCR product line meets rising industry demand driven by trends in precision medicine, infectious disease monitoring, and advanced therapy development. The company's all-in-one and high-throughput systems address key challenges facing laboratories today, including accuracy, speed, and ease of use.
To learn more about the new QX Continuum and QX700 series, as well as Bio-Rad’s comprehensive portfolio of digital PCR instruments, consumables, and assays visit: bio-rad.com/dropletdigitalPCR